Pasteur dengue vaccine not 100% but encourages competition
This article was originally published in Scrip
When Sanofi Pasteur announced in July 2012 that its recombinant dengue fever vaccine CYD-TDV had completed a Phase II study in Thailand, it came as somewhat of a surprise that the efficacy of the vaccine did not approach 100%. With the publication of the results from that trial in the 11 September issue of The Lancet, it is now clear the fly in the ointment is primarily the vaccine's lack of efficacy against the DENV2 subtype of dengue, one of four virus serotypes against which the vaccine was designed.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.